FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

FDA 규제 화합물

이 화합물은 FDA 승인 또는 규제 대상입니다. 유효한 처방 없이 구매하는 것은 연방법 위반일 수 있습니다. 지역 법규를 확인하세요.

HCG

Human Chorionic Gonadotropin / Pregnyl / Novarel

Sexual Health

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) activity at the Leydig cells. It is FDA-approved for the treatment of hypogonadism, cryptorchidism in pediatric patients, and as a fertility treatment to induce ovulation. In clinical practice, it is widely used alongside testosterone replacement therapy to maintain testicular function and intratesticular testosterone production.

작용 메커니즘

Glycoprotein hormone that mimics luteinizing hormone (LH) action. In males, stimulates Leydig cells to produce testosterone. In females, triggers ovulation and supports corpus luteum progesterone production. Maintains testicular function during exogenous hormone use.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Male research protocols use 250-500 IU 2-3 times weekly to maintain testicular function. Female protocols (fertility) use 5,000-10,000 IU to trigger ovulation. Intramuscular or subcutaneous injection.

연구 노트

Clinical Research Status

HCG holds longstanding FDA approval for multiple indications including male hypogonadism, prepubertal cryptorchidism, and female infertility (ovulation induction). It has been used clinically since the 1930s with an extensive safety database spanning decades. Compounded HCG was temporarily restricted by the FDA in 2020 under the Biologics Control Act, though branded pharmaceutical versions (Pregnyl, Novarel) remain available.

Key Published Findings

Studies demonstrate that HCG at doses of 500-1500 IU two to three times weekly maintains intratesticular testosterone levels and spermatogenesis during exogenous testosterone administration. Research confirms LH receptor activation by HCG stimulates both testosterone production and supports Sertoli cell function critical for sperm maturation. In fertility contexts, HCG triggers final oocyte maturation at doses of 5,000-10,000 IU as a surrogate LH surge.

Safety Profile

Common side effects include injection site pain, headache, and mood fluctuations related to hormonal changes. Prolonged use at high doses can cause Leydig cell desensitization, potentially reducing endogenous LH receptor sensitivity. Gynecomastia may occur due to downstream aromatization of increased testosterone, and rare cases of ovarian hyperstimulation syndrome occur in female fertility use.

Comparison to Related Compounds

Unlike gonadorelin which stimulates the pituitary to release LH, HCG acts directly at the gonadal level bypassing the hypothalamic-pituitary axis. This makes HCG effective even in patients with suppressed gonadotropin release from exogenous testosterone use. Compared to recombinant LH (Luveris), HCG has a longer half-life of approximately 24-36 hours and is significantly less expensive.

Community Observations

HCG is considered essential by many TRT practitioners for maintaining testicular size and preserving fertility potential during testosterone therapy. Typical protocols use 250-500 IU two to three times per week alongside testosterone, with some clinicians preferring every-other-day dosing. The 2020 regulatory changes affecting compounded HCG availability created significant disruption for patients relying on lower-cost compounded preparations.

반감기

~24-36 hours

재조성

Bacteriostatic water (BAC) provided with kit

보관

건조한 상태

Refrigerate 2-8C.

재조성된 상태

Refrigerate 2-8C. Use within 30 days.

미국 법적 상태

FDA-approved (Rx only)

또는 알려진 이름으로

Human Chorionic GonadotropinPregnylNovarel

자주 묻는 질문

HCG란 무엇인가요?

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) activity at the Leydig cells. It is FDA-approved for the treatment of hypogonadism, cryptorchidism in pediatric patients, and as a fertility treatment to induce ovulation. In clinical practice, it is widely used alongside testosterone replacement therapy to maintain testicular function and intratesticular testosterone production.

HCG는 어떻게 작용하나요?

Glycoprotein hormone that mimics luteinizing hormone (LH) action. In males, stimulates Leydig cells to produce testosterone. In females, triggers ovulation and supports corpus luteum progesterone production. Maintains testicular function during exogenous hormone use.

HCG의 미국 규제 현황은 어떤가요?

FDA-approved (Rx only)

HCG의 반감기는 얼마인가요?

~24-36 hours

HCG의 다른 이름은 무엇인가요?

Human Chorionic Gonadotropin, Pregnyl, Novarel

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기